10-QPeriod: Q1 FY2025

Edwards Lifesciences Corp Quarterly Report for Q1 Ended Mar 31, 2025

Filed May 6, 2025For Securities:EW

Summary

Edwards Lifesciences Corporation reported solid financial results for the first quarter of 2025, with net sales increasing by 6.2% to $1.41 billion, primarily driven by growth in their Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product lines. Diluted earnings per share also saw an increase, reflecting improved operational performance. The company continued its strategic focus on structural heart disease innovations, with recent FDA approval for the SAPIEN 3 platform for asymptomatic severe aortic stenosis patients and CE Mark for the SAPIEN M3 mitral valve replacement system. Financially, the company maintained a strong balance sheet with a significant cash position. While operating activities provided substantial cash flow, driven partly by a tax payment normalization from the prior year, investing activities also saw significant deployment into available-for-sale investments. The company also returned capital to shareholders through share repurchases, including a notable accelerated share repurchase program. However, investors should note ongoing litigation and tax disputes, particularly an IRS examination regarding transfer pricing, which represent potential future financial impacts, although management does not currently believe they will be material adverse events.

Financial Highlights

50 data points
Beta

Revenue

$1.41B

78.7% Gross Margin

Net Income

$356.40M

25.2% Net Margin

EPS (Diluted)

$0.61

Total Assets

$13.02B

Cash & Equivalents

$3.15B

Free Cash Flow

$224.40M

Financial Statements
Beta
Revenue$1.41B
Cost of Revenue$301.60M
Gross Profit$1.11B
R&D Expenses$254.60M
SG&A Expenses$465.70M
Operating Income$394.80M
Net Income$356.40M
EPS (Basic)$0.61
EPS (Diluted)$0.61
Shares Outstanding (Basic)586.90M
Shares Outstanding (Diluted)587.80M

Key Highlights

  • 1Net sales grew 6.2% year-over-year to $1.41 billion, fueled by strong performance in TAVR and TMTT products.
  • 2Diluted earnings per share increased, demonstrating improved profitability.
  • 3The company received FDA approval for the SAPIEN 3 platform for asymptomatic severe aortic stenosis patients and CE Mark for the SAPIEN M3 mitral valve replacement system, highlighting product innovation and expansion.
  • 4Edwards Lifesciences maintained a healthy cash position with $3.14 billion in cash and cash equivalents.
  • 5The company repurchased approximately $308.6 million of treasury stock, including an accelerated share repurchase agreement, indicating a commitment to shareholder returns.
  • 6Significant ongoing litigation and tax disputes, particularly an IRS transfer pricing examination, present potential future financial risks.

Frequently Asked Questions

Revenue growth was primarily driven by increased sales of Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) products. Specifically, higher sales of the Edwards SAPIEN platform, including the SAPIEN 3 Ultra RESILIA valve, and the PASCAL system, alongside the launch of the EVOQUE tricuspid valve replacement system, contributed to the increase.

Edwards Lifesciences received United States FDA approval for the SAPIEN 3 platform for asymptomatic severe aortic stenosis patients. Additionally, the company obtained CE Mark for the Edwards SAPIEN M3 mitral valve replacement system for treating symptomatic mitral regurgitation.

The company faces ongoing litigation, including a securities class action and consolidated derivative actions related to alleged misleading statements. Additionally, there is a significant IRS transfer pricing examination concerning intercompany royalty transactions, with a notice of deficiency issued for $269.3 million (before interest and offset). An assessment from the Israel Tax Authority for approximately $110 million related to a claimed intellectual property transfer also remains a concern. While management currently believes these matters will not have a material adverse effect, their resolution could impact financial statements.

Edwards Lifesciences maintains robust liquidity through cash and cash equivalents ($3.14 billion as of March 31, 2025) and cash from operations. The company has a $750 million revolving credit facility, though none was outstanding. They are also actively returning capital to shareholders through share repurchase programs, including an accelerated share repurchase, and have made significant acquisitions, with future payments tied to milestones.